Xigris Growth Tied To Patient Selection As Hospitals Wrestle With Protocols
Executive Summary
The growth of Xigris will be tied to helping hospitals identify appropriate patients for the sepsis agent, Lilly suggested during a Jan. 24 earnings conference call
You may also be interested in...
Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages
Lilly is planning to publish a series of peer-reviewed Xigris journal articles as part of a continued effort to build market acceptance of the sepsis agent
Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages
Lilly is planning to publish a series of peer-reviewed Xigris journal articles as part of a continued effort to build market acceptance of the sepsis agent
Xigris Medicare “Add-On” Payments Approved; CMS Estimates 50,000 Cases
The Centers for Medicare & Medicaid Services is estimating that the Medicare market for Lilly's Xigris will be $340 mil. in fiscal year 2003